TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06069596

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Natalis Obstetric Lubrican Gel
Description: The obstetric lubricant gel was applied to the vaginal canal with a special applicator at the beginning of the active phase of the labor. The gel used in the study was highly viscose and isotonic with a slight acid pH of 6.0 - 6.7 and contained hydroxyethylcellulose, propylene glycol, glycerin. The gel box contained a sterile syringe (15 ml) and a flexible applicator.
Study: NCT03552471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib Camsylate
Description: Given PO
Study: NCT02363946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.
Study: NCT04340206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: face-to-face support and Chatbot online support group
Description: Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to support adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program. In addition, they meet and get support from their human coach (i.e., psychology student) twice in the face-to-face meetings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: only chat-robot online support group
Description: Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group, no intervention
Description: Behavioral: No intervention
Study: NCT00303524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: Injection 3.6 mg monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: injection 10.8 mg every 3 months
Study: NCT00113568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid tablets (XP12B)
Description: Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
Study: NCT01161316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
Description: Treatment regimen:~mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
Description: Treatment regimen.~mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations.
Study: NCT01655030

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine monohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02341417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.
Study: NCT01588379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls and mothers Afro-centric dance program
Description: African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls, alone
Description: African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter
Description: Both girls and the mothers will receive weekly newsletter containing various health information.
Study: NCT01556087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance
Description: 7 individual sessions aimed at increasing distress tolerance skills

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: 7 individual sessions with didactic health education information
Study: NCT02039596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Study: NCT01021462

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: graded infusion of intravenous glucose
Description: A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12mg/kg/min. Procedure will be identical in Period 1 and Period 2.
Study: NCT01853813

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab and FOLFIRI
Description: The CENTRAL trial is a biologically enriched prospective phase II clinical trial in which patients treated with first-line modified FOLFIRI and bevacizumab will be prospectively stratified according to LDH serum levels.~After written informed consent patients will be enrolled. Patients will be considered evaluable for study aim if response rate was radiologically evaluated at least once during treatment course.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity
Study: NCT03747523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Investigational drug will be administered to eligible participants in a single dose of 200,000 USP units vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Investigational drug will be administered to eligible participants in a single dose of 200,000 USP units vitamin D
Study: NCT00385047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A FMP2.1/AS01B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B FMP2.1/AS02A
Study: NCT00610155

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Dose 75 mg titrated to 150 mg, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol SR
Description: Dose 50mg titrated to 200 mg, bid
Study: NCT01964482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training followed by intake of a protein drink
Study: NCT03901820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Interaction System of Dr App (SIMDA)
Description: A module for the electronic clinical records allowing detection of the potential drug interactions
Study: NCT01609010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m2 rituximab i.v. weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 rituximab i.v. weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-a-2a
Description: 3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5
Study: NCT04849468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Declofenac
Description: evaluating the preemptive effect of intramuscular declofenac on postoperative analgesia in patients undergoing perianal surgeries under saddle block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: evaluating the preemptive effect of intramuscular saline on postoperative analgesia in patients undergoing perianal surgeries under saddle block as control
Study: NCT03192306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Merlin
Description: glycolic acid/ethanol solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: Ethanol solution
Study: NCT01152749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Single-dose of new NRT product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Single-dose of new NRT product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Gum
Description: Single-dose of marketed nicotine gum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Gum
Description: Single-dose of marketed nicotine gum
Study: NCT04516343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Ankle Assist Device (RAAD)
Description: The RAAD (Robotic Ankle Assist Device) is an intelligent, powered ankle device designed to increase independence, mobility, and deliver gait training to children with movement disorders, such as CP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Ankle Assist Device (RAAD)
Description: The RAAD (Robotic Ankle Assist Device) is an intelligent, powered ankle device designed to increase independence, mobility, and deliver gait training to children with movement disorders, such as CP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Ankle Assist Device (RAAD)
Description: The RAAD (Robotic Ankle Assist Device) is an intelligent, powered ankle device designed to increase independence, mobility, and deliver gait training to children with movement disorders, such as CP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Ankle Assist Device (RAAD)
Description: The RAAD (Robotic Ankle Assist Device) is an intelligent, powered ankle device designed to increase independence, mobility, and deliver gait training to children with movement disorders, such as CP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Ankle Assist Device (RAAD)
Description: The RAAD (Robotic Ankle Assist Device) is an intelligent, powered ankle device designed to increase independence, mobility, and deliver gait training to children with movement disorders, such as CP
Study: NCT01532518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant
Description: Nepadutant oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant
Description: Nepadutant oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant
Description: Nepadutant oral solution
Study: NCT02283268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand Factor (rVWF)
Description: rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.
Study: NCT02041663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNP
Description: Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
Study: NCT00745342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Teamwork Intervention
Description: Families in the teamwork group received quarterly psychoeducational interventions at regular clinic visits, focusing on promoting family teamwork and reducing diabetes-specific family conflict and diabetes burnout.
Study: NCT02892773

Intervention type: DEVICE
Group type: OTHER
Intervention: Incentive Spirometry
Description: A respiratory therapist will provide instruction on Incentive Spirometry (I.S.) procedure performance before supervised therapy and monitoring begins.~* Study participants will be asked to take 10 deep breaths through the I.S.'s mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated 3 times per therapy session.~* Each I.S. therapy session will last about 15 minutes, 3 times per day.~* Lung monitoring and deep breathing measurements will occur during a scheduled I.S. sessions on day 1, 3, and 5 after surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EzPAP® Positive Airway Pressure
Description: A respiratory therapist will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated 3 times.~* Each EzPAP® therapy sessions will last about 15 minutes, 3 times per day.~* Lung monitoring will occur during a scheduled EzPAP® sessions on day 1, 3, and 5 after surgery.
Study: NCT02682693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 120 mg every 4 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
Study: NCT00921531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide is used for adjuvant therapy for TACE~Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
Study: NCT04821180

Intervention type: PROCEDURE
Intervention: Three and four-part proximal humeral fractures' treatment
Description: Open Reduction and Internal Fixation with angle stable plate PHILOS versus RSA (Reverse Shoulder Arthroplasty

Intervention type: PROCEDURE
Intervention: Three and four-part proximal humeral fractures' treatment
Description: Open Reduction and Internal Fixation with angle stable plate PHILOS versus RSA (Reverse Shoulder Arthroplasty
Study: NCT01615406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc MIP 1404
Description: A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
Study: NCT03023917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord milking
Description: Infants were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
Study: NCT04372433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-202
Description: IO-202 as monotherapy
Study: NCT03858205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive low-dose radiation therapy
Study: NCT02300220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: 500 mg, twice daily for 1 week (oral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule, twice daily for 1 week
Study: NCT04372433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-202 and Azacitidine
Description: IO-202 and azacitidine combination therapy
Study: NCT01302119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690 Topical Solution, 5%
Description: AN2690 Topical Solution, 5%, applied once daily for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solution Vehicle
Description: AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Study: NCT01055769

Intervention type: DRUG
Group type: OTHER
Intervention: Linezolid
Description: 1. Linezolid OS 600 MG~2. Linezolid Tablet 600 MG

Intervention type: DRUG
Group type: OTHER
Intervention: Linezolid
Description: 1. Linezolid Tablet 600 MG~2. Linezolid OS 600 MG
Study: NCT04372433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-202 and Azacitidine + Venetoclax
Description: IO-202 and azacitidine + venetoclax combination therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-202 and Azacitidine
Description: IO-202 and azacitidine combination therapy
Study: NCT02186808

Intervention type: DEVICE
Group type: OTHER
Intervention: Procera® Bridge Zirconia
Description: Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
Study: NCT00047879

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PEG-interferon alfa-2b
Description: 0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection
Study: NCT03023917

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: umbilical cord clamping immediately
Description: umbilical cord was cut immediately after birth
Study: NCT01873404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00010
Description: As specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As specified in the treatment arm
Study: NCT03371862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector [Victoza]
Description: Pilot study of liraglutide in patients with short bowel.
Study: NCT00047879

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PEG-interferon alfa-2b
Description: 0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection

Intervention type: DRUG
Group type: OTHER
Intervention: Thalidomide
Description: Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.

Intervention type: DRUG
Group type: OTHER
Intervention: Thalidomide
Description: Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.
Study: NCT04569773

Intervention type: BEHAVIORAL
Intervention: Impact of Event Scale-Revised
Description: The IES-R is a validated 22-item self-report scale measuring psychological stress reactions after a major life or traumatic event.1-3Items are rated with reference to the past 7 days on a 5-point scale, ranging from 0 to 4. Three subscale scores are calculated by taking the mean of the item responses: Intrustion (8 items), Avoidance (8 items), and Hyperarousal (6 items). The total score is similarly computed by taking the mean of all 22 items. All scores range from 0 to 4, with higher scores indicating higher event-related distress. Internal consistency estimates(Cronbach's alpha) for all scores range between 0.79 to 0.92.
Study: NCT01767246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFS Algorithm treatment
Description: Physical Therapy treatment for Patellofemoral Syndrome based upon a treatment algorithm. that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patients with the goal of have low fear avoidance beliefs, flexibility, body mechanics, and strength.